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Abstract
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy with  
a prevalence of 1:500 (0.2%) in the general population. Sudden cardiac death (SCD) is the most  
feared presentation of HCM. Therefore, it is essential to identify individuals at high risk in 
order to prevent SCD. The absence of conventional risk factors does not nullify the risk of HCM 
related SCD. Although echocardiography is currently the most widely used imaging modality, 
cardiac magnetic resonance (CMR) allows detailed characterization of the HCM phenotype, 
which makes it possible to differentiate HCM from other causes of left ventricular hypertrophy. 
CMR has the potential to further refine risk stratification. Late gadolinium enhancement 
(LGE) on CMR is a high-risk feature and there is emerging data to suggest that the presence of 
LGE should be employed as a marker for major adverse outcomes such as SCD, arrhythmias, 
systolic and diastolic heart failure. Hence, LGE on CMR may be considered an additional risk 
factor for SCD in HCM patients and should be incorporated in decision-making for implant-
able cardioverter defibrillator implantation to aid primary prevention. Novel markers such as 
the extent of myocardial fibrosis on CMR must be accounted for comprehensive risk stratifica-
tion of HCM patients. The purpose of this review is to discuss the current status and emerging 
role of CMR in HCM. (Cardiol J 2016; 23, 3: 250–263)
Key words: hypertrophic cardiomyopathy, sudden cardiac death, myocardial  
fibrosis, cardiovascular magnetic resonance, T1-mapping, gadolinium contrast
Introduction
Hypertrophic cardiomyopathy (HCM) is the 
most common genetic cardiomyopathy with a prev-
alence of 1:500 (0.2%) in the general population [1]. 
It is characterized by inappropriate myocardial wall 
thickening and is usually caused by mutations in 
genes encoding proteins of the cardiac sarcomere. 
It is transmitted by an autosomal dominant pattern 
of inheritance in 60% of cases. The heterogeneity 
in penetrance, phenotypic expression, and clinical 
presentation suggests a role of additional genetic, 
epigenetic and environmental factors in the patho-
genesis. Defective sarcomere proteins impair the 
function of cardiac myocytes, ultimately resulting 
in left ventricular hypertrophy (LVH) with asym-
metric ventricular septal hypertrophy being the 
most common phenotype [2, 3]. HCM has a broad 
range of clinical manifestations of HCM. Most 
patients remain undiagnosed or asymptomatic 
with normal life expectancy [4]. However, symp-
tomatic patients present with palpitations, chest 
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pain, exertional dyspnea, or sudden cardiac death 
(SCD). It is the most common cause of SCD in 
the young and one of the leading causes of heart 
failure (HF) disability at 5–10 years of age [5]. 
The symptoms occur due to systolic or diastolic 
dysfunction, left ventricular (LV) outflow tract 
obstruction, microvascular ischemia or ventricular/ 
/supraventricular arrhythmias [6]. Although annual 
mortality rates range from 1% to 5%, a significant 
number of patients are at risk for adverse outcomes [7]. 
Therefore, it is essential to identify the risk of 
SCD and plan implantable cardioverter defibrilla-
tor (ICD) in those patients who are at high risk. 
Although echocardiography is commonly used, 
cardiac magnetic resonance (CMR) is considered 
to be the gold standard for evaluating ventricular 
mass, volumes, and ejection fraction (EF). Unlike 
echocardiography, CMR has an advantage in that 
there are no limitations from poor acoustic win-
dows. The purpose of this review is to discuss the 
current status and emerging role of CMR in HCM.
Diagnosis of HCM
Echocardiography has been the most valuable 
screening tool to evaluate HCM, as it is widely 
available, bedside technique, which is relatively 
cheap and non-ionizing. In addition, it provides 
useful information for risk stratification, treatment, 
and follow-up of patients.
Cardiac magnetic resonanse  
for diagnosis of LVH
Although asymmetrical septal hypertrophy 
is a common phenotype, accurate assessment of 
LVH by echocardiography may not be possible in all 
segments in all patients. It is hard to differentiate 
the lateral epicardial border of the LV myocardium 
from the adjacent thoracic parenchyma and the 
epicardial border of the posterior septum in the 
area of insertion of the right ventricular (RV) free 
wall by echocardiography due to loss of spatial 
resolution. CMR is not limited by such constraints 
and it is superior to echocardiography for assessing 
LV wall thickness on the anterior wall, posterior 
septum and apex of the heart due to its tomographic 
imaging capability and higher spatial resolution 
[3, 8]. Maron et al. [8] described different patterns of 
LVH in 333 HCM patients utilizing CMR. The most 
common location of hypertrophy (in 70% patients) 
was the confluence of the basal anterior septum 
with the adjacent anterior free LV wall. The next 
most common site was the posterior septum at 
the mid-ventricular level [3]. Thus, CMR allows 
detailed characterization of the HCM phenotype 
(Figs. 1, 2) and helps differentiate HCM from other 
causes of LVH.
Differentiating HCM from athlete’s heart
Cardiac magnetic resonanse has several ad-
vantages as compared to echocardiography for the 
evaluation of LVH in trained athletes. If there is an 
ambiguity regarding the borderline LV wall thick-
Figure 1. Short axis view on cardiac magnetic resonance 
demonstrating concentric left ventricular hypertrophy.
Figure 2. Four chamber view on cardiac magnetic 
resonance demonstrating mid-ventricular hypertrophy 
(white asterisk) and an apical aneurysm (white arrow).
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ness either due to athletic training or HCM, the 
presence of scar/enhancement on CMR would sug-
gest the presence of HCM. Interruption or cessa-
tion of intense physical activities in trained athletes 
(deconditioning) for short [9] or long periods [10] of 
time results in restoration of normal LV cavity size 
due to regression of LVH. However, alteration in 
physical activity does not affect LV wall thickness 
in HCM. CMR can be used to detect serial changes 
in LV wall thickness during deconditioning of the 
heart in athletes [10].
Detection of myocardial fibrosis with late 
gadolinium enhancement using CMR
Myocardial fibrosis is defined as a significant 
increase in the collagen volume fraction of myo-
cardial tissue, which is common in advanced car-
diac disease [11]. Replacement (focal and diffuse) 
fibrosis or interstitial fibrosis are two types of 
myocardial fibrosis commonly seen in HCM. Scar-
ring or replacement fibrosis is the accumulation 
of collagen corresponding to necrotic or damaged 
myocyte. Interstitial fibrosis is diffusely distributed 
in the extracellular space. It is predicted that trans-
forming growth factor-beta 1 triggers production of 
extracellular matrix proteins leading to myocardial 
fibrosis in HCM [12]. Myocardial fibrosis has been 
recognized as a predictor of adverse clinical out-
comes in HCM patients and therefore its quantifica-
tion has gained great importance. Endomyocardial 
biopsy, the gold standard invasive method, is used 
to assess interstitial collagen accumulation. CMR 
is emerging as a gold standard among the non-
invasive imaging modalities to visualize the extra-
cellular compartment of myocardium and quantify 
myocardial fibrosis. In a study of 29 patients by 
Moravsky et al. [13], the significant correlation 
was seen between quantitative assessment of 
myocardial fibrosis by histological methods and late 
gadolinium enhancement (LGE). The gadolinium 
contrast distributes preferentially to the extracel-
lular compartment of the myocardium because it 
is small enough to pass through the capillary wall 
yet large enough to preclude its entry into the cell 
membrane (Fig. 3) [13]. The role of LGE on CMR 
for the prediction of major adverse outcomes such 
as SCD, arrhythmias, systolic and diastolic HF may 
be supported by some emerging data [14–16].
Late gadolinium enhancement and SCD
The performance of conventional risk factors 
for risk stratification of SCD in HCM is known 
to be suboptimal. Hence, it can be challenging to 
accurately identify risk factors which can improve 
the patient selection for prophylactic ICD therapy 
[17]. Contrast-enhanced CMR has emerged as an 
excellent tool for improving risk stratification of 
HCM patients. Although the data are still limited 
in this regard, there are several studies which have 
highlighted that the presence and extent of LGE 
can improve risk stratification of HCM patients 
[14, 18–20]. The relevant studies are summarized 
in Tables 1–4.
The presence and extent of LGE as a marker 
of myocardial fibrosis is a risk factor for SCD in 
HCM patients. Moon et al. [18] showed that greater 
area of LGE (p < 0.001) and the presence of two 
or more risk factors for sudden death (p < 0.02) 
are directly proportional to disease progression in 
HCM patients. Progressive disease was defined as 
a decrease in maximal LV wall thickness by ≥ 5 mm 
and an increase in LV end-systolic dimension by 
≥ 5 mm during 5 or more years of serial follow-up 
with an echocardiogram. In a recent study, Ismail 
et al. [21] have shown that even small increments 
in fibrosis, such as an increase in LGE by 5%, 
significantly increase the risk of SCD. Another 
recent study by Chan et al. [22] virtually estab-
lishes that the extent of LGE is a strong predictor 
of SCD events. When compared with conventional 
risk factors, the extent of LGE was by far the best 
predictor of SCD events. When used in combination 
Figure 3. Short axis view on cardiac magnetic reso-
nance with late gadolinium enhancement demonstrat-
ing patchy enhancement especially prominent in the 
anterior right ventricle insertion point (white arrow).
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with other established predictors, the percentage 
of LGE significantly improved the prediction of 
SCD events. The results showed that increased 
LGE by 10% increases the risk of SCD events by 
40% (HR: 1.46/10% increase in LGE, p = 0.002). 
The incidence of SCD per 1,000 person years was 
directly proportional to the percentage extent of 
LGE: 10 per 1,000 person years with LGE ≤ 10%, 
18 per 1,000 person years with 11–19%, and 
24 per 1,000 person years with ≥ 20% (p = 0.001 
for trend [22]. Hen et al. [23] found a higher rate 
of cardiovascular events including SCD in the 
Japanese population with HCM who had LGE as 
compared to those without LGE (annual events 
rate, 6.2% per year vs. 0.6% per year, p = 0.003).
It is worthwhile to emphasize that the role of 
CMR extends even to those genotypically positive 
patients who have not yet developed the clinical 
signs or symptoms of disease. The presence of 
LGE in genotype(+)/phenotype(–) individuals can 
indicate structural abnormalities in non-hypertro-
phied muscle [24]. However, there is no established 
consensus regarding the definitive diagnostic and 
prognostic role of delayed enhancement for adverse 
disease outcomes like SCD and arrhythmias in 
such a setting.
Late gadolinium enhancement  
and arrhythmias
Myocardial fibrosis serves as an arrhythmo-
genic substrate for dangerous ventricular ar-
rhythmias. The studies showing the relationship 
between LGE and arrhythmias are summarized 
in Tables 1–4. Adabag et al. [15] reported that pa-
tients with LGE had a 7-fold increased risk of non-
sustained ventricular tachycardia as compared to 
those without it (relative risk: 7.3, 95% CI 2.6–20.4, 
p < 0.0001). Hen et al. [23] found a significantly 
higher percentage of arrhythmias in patients with 
LGE compared to patients without LGE in a Japa-
nese cohort of HCM patients (annual events rate, 
2.5% per year vs. 0% per year, p = 0.037). Suk et 
al. [25] demonstrated that the risk of ventricular 
arrhythmias could be indirectly predicted using LV 
mass. The size of myocardial scar and hence the 
risk of arrhythmias was found to be correlated with 
LV mass (r2 = 0.74) and LV wall thickness (r2 = 
= 0.42). A myocardial scar mass of more than 7 g 
on LGE predicted the risk of developing ventricular 
tachycardia with 75% sensitivity and 82% specific-
ity. Kwon et al. [16] independently confirmed an 
increased frequency of arrhythmias using Holter 
monitoring. It was reported that a greater per-
centage of patients with LGE had documented 
arrhythmias compared to those without LGE (27% 
vs. 5%, p = 0.03). Leonardi et al. [26] devised 
a scoring system for quantitative assessment of LGE 
in HCM known as Delayed contrast enhancement 
score. Points were given to each segment based 
on the percentage of LGE (i.e. 0 — absence of 
LGE; 1 — < 25% LGE; 2 — 25–50% of LGE; and 
3 — > 50% of LGE). The total score comprised of 
individual scores from all segments. Patients were 
divided into two main groups: group R (risk) with 
risk factors and group LR (low risk) without any 
risk factors for SCD. Group R was further divided 
into high-risk (HR) and intermediate risk (IR) sub-
populations. The HR subgroup included patients 
with prior history of cardiac arrest or sustained 
ventricular tachycardia and the presence of at least 
two other risk factors, whereas the IR subgroup 
included patients with only one risk factor. In the 
analysis conducted by Leonardi et al. [26], using 
delayed contrast enhancement score, LGE was 
also the only independent predictor of ventricular 
arrhythmias (OR: 1.073, 1.023–1.125, p = 0.004) 
in the multivariable analysis.
Late gadolinium enhancement  
and systolic dysfunction
Systolic impairment in HCM results from re-
placement fibrosis, which occurs as a consequence 
of microvascular ischemia and myocyte death [27]. 
Sarcomere mutations cause metabolically ineffi-
cient contractions and myocyte energy depletion 
which can further contribute to systolic dysfunction 
by triggering apoptosis and collagen deposition 
[28, 29]. Therefore, the extent of LGE can predict 
the risk of systolic dysfunction. Various studies 
have analyzed the relationship between LGE and 
systolic dysfunction, and they are summarized in 
Tables 1–4.
The systolic dysfunction can occur at any 
point during HCM. Chan et al. [22] described the 
risk of development of systolic dysfunction in 
end-stage HCM patients. Every 10% increase in 
LGE resulted in a significant decrease in systolic 
function (HR: 1.80, 1.40–2.40, p < 0.03). In the 
prospective cohort study conducted by Ismail et al. 
[21] in HCM patients with LV dysfunction, there 
was evidence of fibrosis on CMR. Olivotto et al. 
[30] demonstrated that LGE predicts adverse LV 
remodeling in HCM patients and it is negatively 
correlated to EF. A subgroup of HCM patients 
(NYHA I or II) with EF 50–65% are in the transi-
tion phase towards advanced LV remodeling and 
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systolic failure. Therefore, regular clinical surveil-
lance and prophylactic therapies have fundamental 
importance in the management of these patients. 
In another study by Conte et al. [31], patients were 
divided into three groups according to the number 
of segments positive for LGE (first group, 0.3 ± 
± 0.4; second group, 2.2 ± 0.4; third group, 5.2 ± 
± 1.9 segments). The percentage of patients with 
EF < 50% as assessed by CMR, in these groups 
was: group 1 (4%), group 2 (4%), group 3 (17%), p = 
= 0.02. Thus, it was suggested that patients who 
had a large extent of LGE on CMR had higher risk 
of systolic dysfunction. While analyzing the rela-
Table 2. Patient demographics.
Author (year) Age (mean ± 
standard devia-
tion) [years]
Male
n (%)
Arrhythmias
n (%)
Mortality during follow-up
n (%)
Motoyasu et al. 
(2008)
57.7 ± 9.8 13 (76) – –
Chan et al.  
(2014)
46 ± 17 85 (63) NSVT 204 (20)  
AF 159 (12)
HCM related SD 14 (1.0) 
Aborted arrest 6 (0.5) 
ICD discharge (VT/VF) 17 (1.3) 
HF death 6 (0.5) 
HT 9 (0.7) 
End-stage HCM 87 (7) 
NYHA class III/IV 99 (9) 
NCD 21 (1.6)
Ismail et al.  
(2014) 
56.3 (median) 498 (70) AF 22 (3.2) 
NSVT 38 (5.4) 
–
Adabag et al. 
(2008) 
41 ± 16 129 (73) –
Olivotto et al. 
(2010)
42 ± 17 218 (70) –
Conte et al.  
(2011) 
53 ± 17 86 (69) NSVT 20/182, p = 0.001 
AF 17/182, p = 0.19
–
Soler et al. (2006) 49.55 ± 14.24 33 (62) – –
Maron et al. (2008) 42 ± 17 144 (71) – –
Hen et al. (2014) 59 ± 17 214 (62) AF 65 (18.8) –
Suk et al. (2008) 54 ± 8 17 (68) – –
Bruder et al. 
(2010) 
58 149 (61.4) – All-cause mortality 22 (10.0) 
Cardiac mortality 16 (7.2) 
Choudhury et al. 
(2000) 
39 (median age) 12 (57) – None
Moon et al.  
(2003)
47 ± 16  
(range 15–73)
37 (70) NSVT on Holter  
monitor 11 (21%) 
Documented sustained 
VT/VF 3 (6%)
Kwon et al. (2009) 51 ± 14 37 (62)
Leonardi et al. 
(2009) 
42 ± 15 82 (76)
AF — atrial fibrillation; HCM — hypertrophic cardiomyopathy; ICD — implantable cardioverter defibrillator; HF — heart failure; HT — heart 
transplantation; NCD — non cardiac death; NSVT — non-sustained ventricular tachycardia; NYHA — New York Heart Association; SD — sud-
den death; VT/VF— ventricular tachycardia/ventricular fibrillation
tionship between delayed enhancement and con-
tractile functions in 53 HCM patients with CMR, 
Soler et al. [32] showed that significant correlations 
existed between delayed enhancement (DE) and 
hypokinetic segments (r = 0.3, p < 0.05). Maron 
et al. [33] demonstrated in a large cohort of HCM 
patients the association of LGE and presence of HF 
symptoms (p = 0.05) along with LV systolic dys-
function (p = 0.001). Hen et al. [23] stratified pa-
tients into three groups according to the LGE score 
(no LGE, 0; mild LGE, 1–3; marked LGE, > 4). 
LGE was converted to scores on a scale of 0 to 
17, as the sum of the segments in the 17-segment 
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model showing LGE. The HF rate was higher in 
marked LGE vs. mild LGE groups (4.6% per year 
vs. 1.0% per year vs. 0.6% per year, p = 0.008). Ac-
cording to Choudhury et al. [20], the extent of LGE 
modestly correlates with EF (r = –0.64, p < 0.001).
Late gadolinium enhancement  
and diastolic dysfunction
It is well established that diastolic dysfunc-
tion precedes systolic dysfunction in the course 
of HCM. Motoyasu et al. [34] showed that strong 
negative correlation exists between LGE and di-
astolic dysfunction evidenced by decreased peak 
filling rate (r = –0.86, p < 0.01).
The role of T1 mapping for detection  
of diffuse myocardial fibrosis in HCM
Endomyocardial biopsy, the gold standard for 
myocardial fibrosis, is an invasive procedure associ-
ated with morbidity, sampling error and sampling 
limitations [35]. Therefore, myocardial fibrosis is 
preferably determined using LGE. Although LGE 
remains an excellent tool for detecting focal myo-
cardial fibrosis, detection of diffuse fibrosis (Fig. 4) 
remains challenging since the normal myocardium 
is used as a reference to highlight patchy areas of 
focal myocardial fibrosis [36]. Extracellular volume 
(ECV) quantification by T1 mapping with CMR 
has overcome this limitation of LGE for detect-
ing diffuse fibrosis in HCM. ECV measures T1 
relaxation time, which is based on the molecular 
environment of water molecules. Every tissue has 
its characteristic T1 relaxation time, but depending 
on the pathophysiological state, it can vary within 
the same tissue. ECV can be measured with and 
without contrast and has shown promising results 
for the detection of myocardial fibrosis. Myocardial 
T1 measurement without the use of gadolinium 
contrast agents is known as native T1, which shows 
cellular and extracellular portions of the myocar-
dium. T1 measurement at a point of time after 
giving a bolus of contrast is known as post contrast 
T1 and can reveal myocardial properties mostly at 
the cellular level [37]. Post-contrast T1 values are 
shorter than pre-contrast or native T1 images due 
to a small amount of gadolinium contrast being left 
in the myocardial interstitium during slow renal 
washout. Renal clearance of gadolinium, hemato-
crit, contrast dosage and time measurements are 
potential confounding variables for post contrast 
T1 [38]. T1 mapping is done systematically in 
which pixel intensity is directly proportional to T1 
relaxation time of the corresponding myocardial 
voxel. This leads to signal quantification of each 
myocardial voxel on a standardized scale with high 
resolution. ECV measurements also hold strong 
histological validation and closely correlate with 
collagen volume fraction [39]. ECV quantification 
by T1 mapping has significant prognostic impli-
cations. Wong et al. [40] have demonstrated an 
association between myocardial extracellular ex-
pansion and adverse clinical outcomes using ECV. 
T1 mapping techniques have another advantage of 
detecting diffuse fibrosis at early stages of the dis-
ease. Compared to LGE images, T1 mapping CMR 
techniques allow us to eliminate the influences of 
windowing and variations in signal enhancement 
by directly measuring the underlying T1 relaxation 
times. Therefore, it allows signal quantification 
(in ms) on a standardized scale of each myocardial 
voxel to characterize myocardial tissue.
Conclusions
Echocardiography is currently the most widely 
used imaging modality in HCM. Although echocar-
diography is an excellent non-invasive modality, 
there are shortcomings in the comprehensive 
Figure 4. Short axis view on cardiac magnetic reso-
nance with late gadolinium enhancement demonstrat-
ing diffuse enhancement of the left ventricular myocar-
dium.
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evaluation and risk stratification of HCM patients 
if utilized exclusively. SCD is the most feared 
outcome of HCM. Myocardial fibrosis in HCM 
can initiate malignant cardiac arrhythmias and 
SCD even in the absence of conventional risk fac-
tors. The extent of LGE on CMR is emerging as 
a potential risk factor for SCD in HCM patients. 
CMR has the additional capability of quantifying 
myocardial fibrosis using novel techniques such 
as T1 mapping. CMR has incremental value and 
is complementary to echocardiography in the 
comprehensive evaluation of patients with HCM.
Conflict of interest: None declared
References
1. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and 
therapeutic implications of genetic testing for hypertrophic cardio - 
myopathy. J Am Coll Cardiol, 2009; 54: 201–211. doi: 10.1016/j.
jacc.2009.02.075.
2. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopa-
thy: The genetic determinants of clinical disease expression. 
Nat Clin Pract Cardiovasc Med, 2008; 5: 158–168. doi: 10.1038/
ncpcardio1110.
3. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet, 
2013; 381: 242–255. doi: 10.1016/s0140-6736(12)60397-3.
4. Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course 
of hypertrophic cardiomyopathy with survival to advanced age. 
J Am Coll Cardiol, 2003; 42: 882–888. 
5. Elliott PM, Poloniecki J, Dickie S et al. Sudden death in hyper-
trophic cardiomyopathy: Identification of high risk patients. J Am 
Coll Cardiol, 2000; 36: 2212–2218. 
6. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guideline 
for the diagnosis and treatment of hypertrophic cardiomyopa-
thy: Executive summary: A report of the American College of 
Cardiology Foundation/American Heart Association Task Force 
on Practice Guidelines. Circulation, 2011; 124: 2761–2796. doi: 
10.1161/CIR.0b013e318223e230.
7. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopa-
thies. N Engl J Med, 2011; 364: 1643–1656. doi: 10.1056/NE-
JMra0902923.
8. Maron MS, Maron BJ, Harrigan C et al. Hypertrophic cardio-
myopathy phenotype revisited after 50 years with cardiovascular 
magnetic resonance. J Am Coll Cardiol, 2009; 54: 220–228. doi: 
10.1016/j.jacc.2009.05.006.
9. Maron BJ, Pelliccia A, Spataro A, Granata M. Reduction in left 
ventricular wall thickness after deconditioning in highly trained 
Olympic athletes. Br Heart J, 1993; 69: 125–128. 
10. Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, 
Culasso F. Remodeling of left ventricular hypertrophy in elite 
athletes after long-term deconditioning. Circulation, 2002; 105: 
944–949. 
11. Schaper J, Speiser B. The extracellular matrix in the failing 
human heart. Basic Res Cardiol, 1992; 87 (suppl. 1): 303–309. 
12. Khan R, Sheppard R. Fibrosis in heart disease: Understanding 
the role of transforming growth factor-beta in cardiomyopathy, 
valvular disease and arrhythmia. Immunology, 2006; 118: 10–24. 
doi: 10.1111/j.1365-2567.2006.02336.x.
13. Moravsky G, Ofek E, Rakowski H et al. Myocardial fibrosis in 
hypertrophic cardiomyopathy: Accurate reflection of histopatho-
logical findings by CMR. J Am Coll Cardiol Cardiovasc Imaging, 
2013; 6: 587–596. doi: 10.1016/j.jcmg.2012.09.018.
14. Bruder O, Wagner A, Jensen CJ et al. Myocardial scar visualized 
by cardiovascular magnetic resonance imaging predicts major ad-
verse events in patients with hypertrophic cardiomyopathy. J Am 
Coll Cardiol, 2010; 56: 875–887. doi: 10.1016/j.jacc.2010.05.007.
15. Adabag AS, Maron BJ, Appelbaum E et al. Occurrence and fre-
quency of arrhythmias in hypertrophic cardiomyopathy in rela-
tion to delayed enhancement on cardiovascular magnetic reso-
nance. J Am Coll Cardiol, 2008; 51: 1369–1374. doi: 10.1016/j.
jacc.2007.11.071.
16. Kwon DH, Setser RM, Popovic ZB et al. Association of myocardi-
al fibrosis, electrocardiography and ventricular tachyarrhythmia 
in hypertrophic cardiomyopathy: A delayed contrast enhanced 
MRI study. Int J Cardiovasc Imaging, 2008; 24: 617–625. doi: 
10.1007/s10554-008-9292-6.
17. Maron BJ. Contemporary insights and strategies for risk strati-
fication and prevention of sudden death in hypertrophic cardio-
myopathy. Circulation, 2010; 121: 445–456. doi: 10.1161/circula-
tionaha.109.878579.
18. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, 
Pennell DJ. Toward clinical risk assessment in hypertrophic 
cardiomyopathy with gadolinium cardiovascular magnetic reso-
nance. J Am Coll Cardiol, 2003; 41: 1561–1567. 
19. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value 
of late gadolinium enhancement in clinical outcomes for hyper-
trophic cardiomyopathy. J Am Coll Cardiol Cardiovasc Imaging, 
2012; 5: 370–377. doi: 10.1016/j.jcmg.2011.11.021.
20. Choudhury L, Mahrholdt H, Wagner A et al. Myocardial scarring 
in asymptomatic or mildly symptomatic patients with hyper-
trophic cardiomyopathy. J Am Coll Cardiol, 2002; 40: 2156–2164. 
21. Ismail TF, Jabbour A, Gulati A et al. Role of late gadolinium 
enhancement cardiovascular magnetic resonance in the risk 
stratification of hypertrophic cardiomyopathy. Heart, 2014; 100: 
1851–1858. doi: 10.1136/heartjnl-2013-305471.
22. Chan RH, Maron BJ, Olivotto I et al. Prognostic value of quanti-
tative contrast-enhanced cardiovascular magnetic resonance for 
the evaluation of sudden death risk in patients with hypertrophic 
cardiomyopathy. Circulation, 2014; 130: 484–495. doi: 10.1161/
circulationaha.113.007094.
23. Hen Y, Iguchi N, Utanohara Y et al. Prognostic value of late gadolini-
um enhancement on cardiac magnetic resonance imaging in Japanese 
hypertrophic cardiomyopathy patients. Circ J, 2014; 78: 929–937. 
24. Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late 
gadolinium enhancement in genotype positive-phenotype nega-
tive hypertrophic cardiomyopathy. J Am Coll Cardiol Cardiovasc 
Imaging, 2012; 5: 119–122. doi: 10.1016/j.jcmg.2011.08.020.
25. Suk T, Edwards C, Hart H, Christiansen JP. Myocardial scar 
detected by contrast-enhanced cardiac magnetic resonance im-
aging is associated with ventricular tachycardia in hypertrophic 
cardiomyopathy patients. Heart Lung Circ, 2008; 17: 370–374. 
doi: 10.1016/j.hlc.2008.03.080.
26. Leonardi S, Raineri C, De Ferrari GM et al. Usefulness of car-
diac magnetic resonance in assessing the risk of ventricular 
arrhythmias and sudden death in patients with hypertrophic 
cardiomyopathy. Eur Heart J, 2009; 30: 2003–2010. doi: 10.1093/
eurheartj/ehp152.
27. Harris KM, Spirito P, Maron MS et al. Prevalence, clinical profile, 
and significance of left ventricular remodeling in the end-stage 
phase of hypertrophic cardiomyopathy. Circulation, 2006; 114: 
216–225. doi: 10.1161/circulationaha.105.583500.
28. Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardi-
omyopathy: A paradigm for myocardial energy depletion. Trends 
Genet, 2003; 19: 263–268. doi: 10.1016/s0168-9525(03)00081-7.
262 www.cardiologyjournal.org
Cardiology Journal 2016, Vol. 23, No. 3
29. Girolami F, Ho CY, Semsarian C et al. Clinical features and 
outcome of hypertrophic cardiomyopathy associated with triple 
sarcomere protein gene mutations. J Am Coll Cardiol, 2010; 55: 
1444–1453. doi: 10.1016/j.jacc.2009.11.062.
30. Olivotto I, Maron BJ, Appelbaum E et al. Spectrum and clinical 
significance of systolic function and myocardial fibrosis assessed 
by cardiovascular magnetic resonance in hypertrophic cardio-
myopathy. Am J Cardiol, 2010; 106: 261–267. doi: 10.1016/j.
amjcard.2010.03.020.
31. Conte MR, Bongioanni S, Chiribiri A et al. Late gadolinium 
enhancement on cardiac magnetic resonance and phenotypic 
expression in hypertrophic cardiomyopathy. Am Heart J, 2011; 
161: 1073–1077. doi: 10.1016/j.ahj.2011.03.022.
32. Soler R, Rodriguez E, Monserrat L, Mendez C, Martinez C. Mag-
netic resonance imaging of delayed enhancement in hypertrophic 
cardiomyopathy: Relationship with left ventricular perfusion and 
contractile function. J Comput Assist Tomogr, 2006; 30: 412–420. 
33. Maron MS, Appelbaum E, Harrigan CJ et al. Clinical profile and 
significance of delayed enhancement in hypertrophic cardiomyo-
pathy. Circ Heart Fail, 2008; 1: 184–191. doi: 10.1161/circheart-
failure.108.768119.
34. Motoyasu M, Kurita T, Onishi K et al. Correlation between late 
gadolinium enhancement and diastolic function in hypertrophic 
cardiomyopathy assessed by magnetic resonance imaging. Circ J, 
2008; 72: 378–383. 
35. Schalla S, Bekkers SC, Dennert R et al. Replacement and reac-
tive myocardial fibrosis in idiopathic dilated cardiomyopathy: 
Comparison of magnetic resonance imaging with right ventricu-
lar biopsy. Eur J Heart Fail, 2010; 12: 227–231. doi: 10.1093/ 
/eurjhf/hfq004.
36. Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, 
Falk RH, Kwong RY. Quantification of extracellular matrix ex-
pansion by CMR in infiltrative heart disease. J Am Coll Car-
diol Cardiovasc Imaging, 2012; 5: 897–907. doi: 10.1016/j.
jcmg.2012.04.006.
37. Moon JC, Messroghli DR, Kellman P et al. Myocardial T1 map-
ping and extracellular volume quantification: A Society for Car-
diovascular Magnetic Resonance (SCMR) and CMR Working 
Group of the European Society of Cardiology consensus state-
ment. J Cardiovasc Magn Reson, 2013; 15: 92. doi: 10.1186/1532-
429x-15-92.
38. Iles L, Pfluger H, Phrommintikul A et al. Evaluation of diffuse 
myocardial fibrosis in heart failure with cardiac magnetic reso-
nance contrast-enhanced T1 mapping. J Am Coll Cardiol, 2008; 
52: 1574–1580. doi: 10.1016/j.jacc.2008.06.049.
39. Miller CA, Naish JH, Bishop P et al. Comprehensive validation 
of cardiovascular magnetic resonance techniques for the as-
sessment of myocardial extracellular volume. Circ Cardiovasc 
Imaging, 2013; 6: 373–383. doi: 10.1161/circimaging.112.000192.
40. Wong TC, Piehler KM, Kang IA et al. Myocardial extracellular 
volume fraction quantified by cardiovascular magnetic resonance 
is increased in diabetes and associated with mortality and inci-
dent heart failure admission. Eur Heart J, 2014; 35: 657–664. doi: 
10.1093/eurheartj/eht193.
www.cardiologyjournal.org 263
Muhammad Umar Kamal et al., Cardiovascular MRI in hypertrophic cardiomyopathy
